Browse Category

NYSE:TRU News 22 December 2025

TransUnion Stock (TRU) Gains Fresh Attention as Institutional Investors Build Stakes and “Data Investments” Thesis Takes Shape

TransUnion Stock (TRU) Gains Fresh Attention as Institutional Investors Build Stakes and “Data Investments” Thesis Takes Shape

December 22, 2025 — TransUnion (NYSE: TRU) is back in focus heading into year-end as a new wave of regulatory filings shows select institutional investors initiating or expanding positions, while fresh valuation commentary highlights the company’s multi-year push into data, analytics, marketing measurement, and fraud prevention. Three developments are setting the tone as of 22.12.2025: Institutional investors: Addenda Capital and Threadgill Financial disclose new TRU stakes Two recent MarketBeat reports summarizing institutional filings highlight new positions in TransUnion during the third quarter: These filings don’t guarantee a coordinated view on the stock—but they do show that, even after a choppy
22 December 2025

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Go toTop